World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
84
Citations
30136
World Ranking
14967
National Ranking
7563

Krzysztof Mrózek publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Krzysztof Mrózek sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 325 publications — 22nd percentile

22% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Krzysztof Mrózek D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Krzysztof Mrózek sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 84 D-Index — 27th percentile

27% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • 2022 - Foreign Member of the Polish Academy of Arts and Sciences

Overview

Krzysztof Mrózek is affiliated with The Ohio State University in the United States. Their research focuses primarily on hematology, molecular biology, and genetics, with a strong emphasis on acute myeloid leukemia (AML) and related blood cancers.

The scientist has contributed extensively to the field of Medicine through numerous publications, with particular expertise in subfields including:

  • Hematology
  • Molecular Biology
  • Genetics
  • Cancer Research
  • Public Health, Environmental and Occupational Health

Key topics of their work cover areas such as:

  • Acute Myeloid Leukemia Research
  • Acute Lymphoblastic Leukemia Research
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Histone Deacetylase Inhibitors Research
  • Chronic Myeloid Leukemia Treatments
  • Cancer Genomics and Diagnostics
  • Protein Degradation and Inhibitors

Their recent papers illustrate ongoing contributions to the understanding of AML and associated genetic factors. Notable publications include:

  • Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance study, 2023, Leukemia
  • Mutational landscape and clinical outcome of patients with de novo acute myeloid leukemia and rearrangements involving 11q23/ KMT2A, 2020, Proceedings of the National Academy of Sciences
  • Additional gene mutations may refine the 2017 European LeukemiaNet classification in adult patients with de novo acute myeloid leukemia aged <60 years, 2020, Leukemia
  • Poor Survival and Differential Impact of Genetic Features of Black Patients with Acute Myeloid Leukemia, 2020, Cancer Discovery
  • Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801, 2020, Blood Advances

The scientist has collaborated frequently with several co-authors, including:

  • Deedra Nicolet
  • Ann-Kathrin Eisfeld
  • Jonathan E. Kolitz
  • Bayard L. Powell
  • Richard M. Stone

Most of their work is published in specialized venues focused on hematologic malignancies and cancer biology, such as:

  • Blood
  • Blood Advances
  • Leukemia
  • bioRxiv (Cold Spring Harbor Laboratory)
  • Journal of Hematology & Oncology

Their research contributions encompass extensive investigation into the genetic and molecular mechanisms of leukemia, aiming to improve classification, prognosis, and treatment approaches for patients with these hematologic cancers.

Best Publications

  • Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)

    John C. Byrd;Krzysztof Mrózek;Richard K. Dodge;Andrew J. Carroll

  • Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia

    K. G. Roberts;Y. Li;D. Payne-Turner;R. C. Harvey

  • IDH1 and IDH2 Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study

    Guido Marcucci;Kati Maharry;Yue-Zhong Wu;Michael D. Radmacher

  • Cytogenetics in acute leukemia

    Krzysztof Mrózek;Nyla A Heerema;Clara D Bloomfield

  • Absence of the Wild-Type Allele Predicts Poor Prognosis in Adult de Novo Acute Myeloid Leukemia with Normal Cytogenetics and the Internal Tandem Duplication of FLT3 A Cancer and Leukemia Group B Study

    Susan P. Whitman;Kellie J. Archer;Lan Feng;Claudia Baldus

  • Adverse Prognostic Significance of KIT Mutations in Adult Acute Myeloid Leukemia With inv(16) and t(8;21): A Cancer and Leukemia Group B Study

    Peter Paschka;Guido Marcucci;Amy S. Ruppert;Krzysztof Mrózek

  • Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?

    Krzysztof Mrózek;Guido Marcucci;Peter Paschka;Susan P. Whitman

  • MicroRNA expression in cytogenetically normal acute myeloid leukemia

    Guido Marcucci;Michael D. Radmacher;Michael D. Radmacher;Kati Maharry;Kati Maharry;Krzysztof Mrózek

  • Prognostic Significance of the European LeukemiaNet Standardized System for Reporting Cytogenetic and Molecular Alterations in Adults With Acute Myeloid Leukemia

    Krzysztof Mrózek;Guido Marcucci;Deedra Nicolet;Kati S. Maharry

  • PAX5 -driven subtypes of B-progenitor acute lymphoblastic leukemia

    Zhaohui Gu;Michelle L. Churchman;Kathryn G. Roberts;Ian Moore

  • Favorable Prognostic Impact of NPM1 Mutations in Older Patients With Cytogenetically Normal De Novo Acute Myeloid Leukemia and Associated Gene- and MicroRNA-Expression Signatures: A Cancer and Leukemia Group B Study

    Heiko Becker;Guido Marcucci;Kati Maharry;Michael D. Radmacher

  • Prognostic Factors and Outcome of Core Binding Factor Acute Myeloid Leukemia Patients With t(8;21) Differ From Those of Patients With inv(16): A Cancer and Leukemia Group B Study

    Guido Marcucci;Krzysztof Mrózek;Amy S. Ruppert;Kati Maharry

  • High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults.

    Kathryn G. Roberts;Zhaohui Gu;Debbie Payne-Turner;Kelly McCastlain

  • Prognostic Significance of, and Gene and MicroRNA Expression Signatures Associated With, CEBPA Mutations in Cytogenetically Normal Acute Myeloid Leukemia With High-Risk Molecular Features: A Cancer and Leukemia Group B Study

    Guido Marcucci;Kati Maharry;Michael D. Radmacher;Krzysztof Mrózek

  • TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.

    Klaus H. Metzeler;Kati Maharry;Michael D. Radmacher;Krzysztof Mrózek

  • Prospective Karyotype Analysis in Adult Acute Lymphoblastic Leukemia: The Cancer and Leukemia Group B Experience

    Meir Wetzler;Richard K. Dodge;Krzysztof Mrózek;Andrew J. Carroll

  • A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403.

    Wendy Stock;Selina M. Luger;Anjali S. Advani;Jun Yin

  • Clinical significance of cytogenetics in acute myeloid leukemia

    K Mrózek;K Heinonen;A de la Chapelle;C D Bloomfield

  • FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications

    Susan P. Whitman;Amy S. Ruppert;Amy S. Ruppert;Michael D. Radmacher;Michael D. Radmacher;Krzysztof Mrózek

  • ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category

    Klaus H. Metzeler;Heiko Becker;Kati Maharry;Kati Maharry;Michael D. Radmacher;Michael D. Radmacher

Frequent Co-Authors

Clara D. Bloomfield
Clara D. Bloomfield The Ohio State University
Bayard L. Powell
Bayard L. Powell Wake Forest University
Andrew J. Carroll
Andrew J. Carroll University of Alabama at Birmingham
Jonathan E. Kolitz
Jonathan E. Kolitz Hofstra University
Richard A. Larson
Richard A. Larson University of Chicago
Guido Marcucci
Guido Marcucci City Of Hope National Medical Center
Richard Stone
Richard Stone Harvard University
Susan P. Whitman
Susan P. Whitman The Ohio State University
Michael A. Caligiuri
Michael A. Caligiuri City Of Hope National Medical Center
John C. Byrd
John C. Byrd University of Pittsburgh Cancer Institute

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re considering Medicine in the USA, several online degrees and related healthcare pathways offer flexible entry routes. For non-nursing graduates seeking advanced roles, direct entry msn programs allow you to earn a Master’s in Nursing without a prior nursing degree, often in a streamlined format.

Aspiring nurses looking for accessible education options can explore the easiest rn program to get into and schools that offer less competitive admissions. There are also nursing programs without teas or HESI exams, ideal for students wanting to avoid lengthy entrance requirements.

Beyond direct patient care, a career in medical administration is possible through online certifications. Accredited options like accredited medical billing and coding schools with financial aid help students quickly enter the workforce in support roles with strong job demand.

From clinical roles to healthcare administration, these flexible options expand your career possibilities in the growing US healthcare sector.

Best Scientists Citing Krzysztof Mrózek

Trending Scientists

Recently Published Articles